KRAS: Mutations in exon 2 of KRAS are reported in 40% of CRC with codon 12 and 13 identified as the two hotspots accounting for about 95% of all mutation
types. These presence of these mutations predict a lack of response to EGFR inhibitors cetuximab and panitumumab therapies (The Lancet Oncology (2014)
15(10): 1065-75; New England Journal of Medicine (2013) 369(11) 1023-34). Based on the clinically available information, the National Comprehensive Cancer
Network (NCCN) recommends all patients with metastatic colorectal cancer have KRAS/NRAS genotyping and, if positive, to not be treated with EGFR inhibitors
(cetuximab or panitumumab).